- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02061878
A Study to Evaluate the Effect of Bexarotene on Beta-Amyloid and Apolipoprotein E Metabolism in Healthy Subjects
A Randomized Controlled Study to Evaluate the Effect of Bexarotene - an RXR Agonist - on Beta-Amyloid and Apolipoprotein E Metabolism in Healthy Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a double blinded, investigational drug study designed to measure the effect of bexarotene on the clearance of Aβ total and production of apoE in the human brain of young, healthy individuals with the APOE3/3 genotype. From the date of initial subject recruitment to the issuance of a final study report and closeout activities, the expected total study duration is 6 to 10 months.
Each participant will be screened for eligibility and randomized to receive either oral bexarotene or placebo control ("Test Article").The study has the potential to demonstrate the pharmacodynamic properties of a novel treatment approach to Alzheimer's disease. The primary biomarker measurements obtained from this study are believed to be highly dynamic and able to provide a rapid read-out of the biologic activity of the candidate therapeutic under study. In addition, exploratory analysis will involve a proteomics-based screen to identify proteins within both blood and CSF that are induced by the Test Article, thereby potentially identifying new biomarkers that can be used in future clinical trials to demonstrate bexarotene action and target engagement.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
Orlando, Florida, United States, 32806
- Compass Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Young healthy adults (age 21-50)
- APOE3/3 genotype
Exclusion Criteria:
- Contraindications for blood or CSF sampling
- Bleeding disorder or taking anticoagulants/antiplatelets
- Chronic active infection
- Blood donation within the past month
- Active drug/alcohol dependence or abuse history with in the last 12 months
- Thyroid dysfunction
- High triglycerides (>3.5 mmol/L)
- High cholesterol (>4.0 mmoL/L)
- Leukopenia, including low neutrophil count (<3 x 10^9/L)
- Neurological or psychiatric disorders
- Homeless or prisoner
- Pregnancy
- Incapable of self-informed consent
- Blood borne disease (HIV, Hepatitis)
- Actively smoking and incapable of using nicotine patches
- Known drug allergy to pain medication or local anesthetic
- Subjects that have participated in another study in the last 30 days
- Abnormalities in lumbar spine previously known within 12 months
- APOE2 or APOE4 allele
- Abnormal EKG
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Bexarotene
The subjects will be administered three (3) capsules of Targretin™ (75 mg/capsule) on a twice daily basis (450 mg/day) for five days
|
Marketed product Targretin® soft gelatin capsule (75mg/capsule) is over-encapsulated in a size AA-el Swedish orange capsule.
The subjects will be administered three (3) capsules of Targretin™ (75 mg/capsule) on a twice daily basis (450 mg/day) for five days.
Other Names:
|
Placebo Comparator: Placebo
The subjects will be administered three (3) capsules of Avicel PH on a twice daily basis (450 mg/day) for five days.
|
The subjects will be administered three (3) capsules of Avicel PH on a twice daily basis (450 mg/day) for five days.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area under the effect curve for newly generated beta-Amyloid (clearance phase),
Time Frame: 21 - 48 hr
|
Area under the effect curve from 21-48h for newly generated beta-Amyloid (clearance phase), which is computed for each individual as the area under the curve of the clearance portion of the labeled beta-Amyloid curve between 21 hour and 48 hours, normalized by plasma free leucine levels.
|
21 - 48 hr
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fractional clearance rate of beta-Amyloid peptide in CNS
Time Frame: 21 - 36 hrs
|
Fractional clearance rate (FCR) of beta-Amyloid peptide in CNS, computed for each individual as the slope of the natural logarithm of the clearance portion of the labeled beta-Amyloid curve between 21 hours and 36 hours 2) AUEC0-24 of apoE: Area under the effect curve from 0-24h for newly generated apoE (production phase) 3) Fractional synthesis rate (FSR) of apoE protein in CNS 4) Aβ and apoE concentrations: CSF beta-Amyloid and apoE concentrations for each time point 5)Size of apoE-containing high density lipoprotein particles in CSF as assessed by native PAGE 6) Labeled/Unlabeled Leu ratio (% of 13C6 Leu) in plasma and CSF for 48 hours following start of 13C6 Leu administration 7) Bexarotene concentrations in blood and CSF 8) Plasma beta-Amyloid total and apoE concentrations at baseline compared to final plasma beta-Amyloid total and apoE concentrations
|
21 - 36 hrs
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Exploratory Endpoint
Time Frame: 5 days
|
AUEC0-18 for newly generated beta-Amyloid (production phase)
|
5 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Craig T Curtis, MD, Compass Research
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- REXCEPTOR-101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer's Disease
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedTerminatedAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedCompletedAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited States
-
University of Southern CaliforniaAlzheimer's Therapeutic Research Institute; American Heart Association; Schaeffer...RecruitingDementia | Alzheimer Disease | Prodromal Alzheimer's Disease | Preclinical Alzheimer's DiseaseUnited States
-
University of Southern CaliforniaNational Institute on Aging (NIA); Alzheimer's Therapeutic Research Institute; Brigham and Women's Hospital and other collaboratorsActive, not recruitingDementia | Alzheimer Disease | Prodromal Alzheimer's Disease | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedTerminatedAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedCompletedAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
University of Southern CaliforniaNational Institute on Aging (NIA); Alzheimer's Therapeutic Research Institute; Alzheimer's Clinical Trials Consortium (ACTC)Enrolling by invitationPreclinical Alzheimer's Disease | Early Preclinical Alzheimer's DiseaseUnited States
-
University Hospital, BordeauxMinistry for Health and Solidarity, FranceCompletedAlzheimer's Disease (AD) | Alzheimer's Disease (AD) Related DisordersFrance
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's Disease | Normal CognitionUnited States
Clinical Trials on Bexarotene
-
Ligand PharmaceuticalsCompleted
-
Eisai Inc.CompletedNon-small Cell Lung CancerCanada, United States, United Kingdom, Australia, Israel, Russian Federation, Czech Republic, France, Greece, Hungary, Poland
-
Beersheva Mental Health CenterCompleted
-
Baylor Breast Care CenterNational Cancer Institute (NCI)Completed
-
Fox Chase Cancer CenterLigand PharmaceuticalsTerminatedParapsoriasisUnited States
-
Boston UniversityLigand PharmaceuticalsCompletedCutaneous T-Cell LymphomaUnited States
-
University of Medicine and Dentistry of New JerseyLigand PharmaceuticalsCompleted
-
Georgetown UniversityDaiichi Sankyo, Inc.Terminated
-
Dartmouth-Hitchcock Medical CenterBristol-Myers Squibb; Ligand PharmaceuticalsTerminatedCarcinoma, Non-small-cell LungUnited States
-
Vanderbilt UniversityCompletedMycosis Fungoides | Sezary Syndrome | Cutaneous T-cell LymphomaUnited States